Wade P. Smith

Wade P. Smith

Auto-generated profile, based on publicly available information

Wade P. Smith

Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Translational Lung Cancer Research
Verified
Journal Article
Closed access
PDF file
WSWade P. Smith
Wade P. Smith
PRPatrick J. Richard
Patrick J. Richard
JZJing Zeng
Jing Zeng
SASmith Apisarnthanarax
Smith Apisarnthanarax
RRRamesh Rengan
Ramesh Rengan
MPMark H. Phillips
Mark H. Phillips
Background:Although proton radiation treatments are more costly than photon/X-ray therapy, they may lower overall treatment costs through reducing rates of severe toxicities and the costly management of those toxicities. To study this issue, we created a decision-model comparing proton vs. X-ray radiotherapy for locally advanced non-small cell lung cancer patients. Methods:An influence diagram was created to model for radiation delivery, associated 6-month pneumonitis/esophagitis rates, and overall costs (radiation plus toxicity costs). Pneumonitis (age, chemo type, V20, MLD) and esophagitis (V60) predictors were modeled to impact toxicity rates. We performed toxicity-adjusted, rate-adjusted, risk group-adjusted, and radiosensitivity analyses. Results:Upfront proton treatment costs exceeded that of photons [$16,730.37 (3DCRT), $23,893.83 (IMRT), $41,061.80 (protons)]. Based upon expected population pneumonitis and esophagitis rates for each modality, protons would be expected to recover $1,065.62 and $1,139.63 of the cost difference compared to 3DCRT or IMRT. For patients treated with IMRT experiencing grade 4 pneumonitis or grade 4 esophagitis, costs exceeded patients treated with protons without this toxicity. 3DCRT patients with grade 4 esophagitis had higher costs than proton patients without this toxicity. For the risk group analysis, high risk patients (age >65, carboplatin/paclitaxel) benefited more from proton therapy. A biomarker may allow patient selection for proton therapy, although the AUC alone is not sufficient to determine if the biomarker is clinically useful. Conclusions:The comparison between proton and photon/X-ray radiation therapy for NSCLC needs to consider both the up-front cost of treatment and the possible long term cost of complications. In our analysis, current costs favor X-ray therapy. However, relatively small reductions in the cost of proton therapy may result in a shift to the preference for proton therapy.

8 November 2018 in Medical Physics
Verified
Journal Article
Closed access
PDF file
OGOlga Gopan
Olga Gopan
WSWade P. Smith
Wade P. Smith
ACAlexei Chvetsov
Alexei Chvetsov
KHKristi Hendrickson
Kristi Hendrickson
AKAlan Kalet
Alan Kalet
EFEric Ford
Eric Ford

17 May 2017 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
WSWade P. Smith
Wade P. Smith
LYLori A. Young
Lori A. Young
MPMark H. Phillips
Mark H. Phillips
MCMichael Cheung
Michael Cheung
LHLia M. Halasz
Lia M. Halasz
JRJason K. Rockhill
Jason K. Rockhill
Multisession stereotactic radiation therapy is increasingly being seen as a preferred option for intracranial diseases in close proximity to critical structures and for larger target volumes. The objective of this study is to investigate the reproducibility of the Extend system from Elekta. A retrospective review was conducted for all patients treated with multisession Gamma Knife between July 2010 and June 2015, including both malignant and benign lesions. Eighty-four patients were treated in this 5-year span. The average residual daily setup uncertainty was 0.48 (0.19) mm. We compare measurements of setup uncertainty from the Extend system to measurements performed with a linac-based approach previously used in our center. The Extend system has significantly reduced setup uncertainty for fractionated intracranial treatments at our institution. Positive results were observed in a small population of edentulous patients. The Extend system compares favorably with other approaches to delivering intracranial stereotactic radiotherapy and is a robust, simple-to-use, and precise method for treating multisession intracranial lesions.